Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIBR 796 BS
Other: high fat standardized breakfast

First Posted Date: 2014-08-05

Last Posted Date: 2014-08-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02208856

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 4

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib

First Posted Date: 2014-08-05

Last Posted Date: 2018-12-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02208843

Locations: 🇷🇴
Sf. Nectarie Oncology Center, Craiova, Craiova, Romania
🇷🇸
Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand

and more 18 locations

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Placebo

First Posted Date: 2014-08-01

Last Posted Date: 2014-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02206659

Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Metalyse

First Posted Date: 2014-08-01

Last Posted Date: 2014-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 987

Registration Number: NCT02206646

Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIF 1149 BS - single rising dose
Drug: Placebo

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02203487

Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: BIBW2 component B
Biological: BIBW2 component A

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02203864

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: hMAb BIWA 4

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT02204059

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Phase 1

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: BI 836845
Drug: Enzalutamide

First Posted Date: 2014-07-30

Last Posted Date: 2023-09-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT02204072

Locations: 🇪🇸
Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain
🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇬🇧
The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom

and more 24 locations

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast

Phase 1

Completed

Conditions: Adenocarcinoma

Interventions: Drug: BIWA 4

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT02204046

Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: 99mTc - labelled hMAb BIWA 4
Drug: 186 Re - labelled hMAb BIWA 4
Drug: unlabelled hMAb BIWA 4 - high dose
Drug: unlabelled hMAb BIWA 4 - low dose
Drug: unlabelled hMAb BIWA 4 - medium dose

First Posted Date: 2014-07-30

Last Posted Date: 2014-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33

Registration Number: NCT02204033

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy